-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iopofosine I-131 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iopofosine I-131 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iopofosine I-131 in Refractory Multiple Myeloma Drug Details: Iopofosine I-131...
-
Product Insights
Net Present Value Model: Cellectar Biosciences Inc’s Iopofosine i-131
Empower your strategies with our Net Present Value Model: Cellectar Biosciences Inc's Iopofosine i-131 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewRhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy,...
-
Product Insights
NewPediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pediatric diffuse intrinsic pontine glioma (DIPG) is a rare and aggressive type of brain tumor that primarily affects children, usually between the ages of five and 10 years. This tumor arises in the brainstem, specifically in the region known as the pons, which controls essential bodily functions such as breathing, heart rate, and muscle control. DIPG tumor location in...
-
Product Insights
NewPontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, drooping of one side of the face, and difficulty...
-
Product Insights
NewEwing Sarcoma – Drugs In Development, 2024
Empower your strategies with our Ewing Sarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Ewing sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing sarcoma can occur at any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewHigh-Grade Glioma – Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...